5-Hydroxymethylated Biomarkers in Cell-Free DNA Predict Occult Colorectal Cancer up to 36 Months Before Diagnosis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Pharmacodynamic ...

A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...

By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.

A new treatment for advanced urothelial cancer was effective with tolerable side effects in an international, multi-center phase 2 clinical trial. The trial results prompted a U.S. Food and Drug ...

Aidixi combined with toripalimab significantly improved progression-free and overall survival in HER2-expressing urothelial carcinoma, regardless of cisplatin eligibility or HER2 expression status.

For patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC), the combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) (EV+P) continued to ...

Investigators reported extended 5-year follow-up data from the CheckMate 274 trial including exploratory MIBC and circulating tumor (ct)DNA data.

Researchers have shown for the first time that it is possible to detect signs of urothelial cancer using a simple, postal, urine test in Lynch Syndrome (LS) patients who are at high risk of developing ...

Histological analysis of the resected specimen diagnosed a Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) with mild lymphocytic submucosal inflammation. Crucially, there was no ...

The median duration of response was 9.2 months. The combination of atezolizumab and split doses of cisplatin and gemcitabine can produce durable responses in patients with locally advanced or ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Atezolizumab monotherapy improved OS compared with chemotherapy among patients with PD-L1-high, ...

Treatment with pembrolizumab plus enfortumab vedotin reduced the risk of disease progression or death by 55% compared with chemotherapy. The Food and Drug Administration (FDA) has accepted for ...